{'fraction_non_alphanumeric': 0.035333087964666915, 'fraction_numerical': 0.026499815973500183, 'mean_word_length': 5.502392344497608, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
PD58-04 EFFECT OF A PROSPECTIVE OPIOID REDUCTION INTERVENTION ON OPIOID PRESCRIBING AND USE AFTER RADICAL PROSTATECTOMY: RESULTS OF THE ORIOLES INITIATIVE

INTRODUCTION AND OBJECTIVES: Opioid pain medications are overprescribed, but little data is available to appropriately tailor post-discharge opioid prescriptions after urologic surgery. The Opioid Reduction Intervention for Open, Laparoscopic, and Endoscopic Surgery (ORIOLES) initiative established an evidence-based reference value for opioid prescribing after radical prostatectomy and implemented a prospective intervention to reduce prescribing and use. The objective of the present study was to report on changes in opioid prescribing and use after intervention in the ORIOLES initiate. METHODS: A prospective, non-randomized, pre-post cohort study of patients undergoing radical prostatectomy for prostate cancer (2017-2018) as part of ORIOLES was conducted. The primary outcome was total oral morphine equivalents (OMEQ) used after surgery with a reference value set to meet the needs of >80% of patients based on the pre-intervention cohort. Surgical approach and predictors of use were assessed via multivariable linear regression and mixed effects models. The post-intervention cohort all received an informational discharge sheet on opioid medications, nursing education, and standardized prescribing based on the reference value. RESULTS: A total of 205 patients were included in the pre-intervention cohort and 87 patients in the post-intervention cohort. Prior to intervention, a median of 225mg OMEQ was prescribed, 22.5mg used, an overall 77% of medication unused, and 9.3% appropriate disposal of leftover medication. About 84% of patients required ⩽112.5mg OMEQ with greater prescribing independently associated with greater opioid use in adjusted models. The post-intervention cohort demonstrated a statistically significant reduction in OMEQ prescribed (-45.5%; mean 226.5mg to 123.4mg). OMEQ used was decreased (-21.5%; mean 52.5mg to 41.2mg) with a slight increase in disposal (+7.6%; 9.3% to 16.9%) though these were not statistically significant with the current sample size. Only 6 (6.9%) patients required additional opioid medication in the post-intervention cohort. CONCLUSIONS: Opioid pain medications are overprescribed relative to actual use by patients after radical prostatectomy with more opioids used when a greater quantity is prescribed. An appropriate baseline reference value for prescriptions after radical prostatectomy is 112.5mg OMEQ, which equates to 15 tablets of oxycodone 5 mg, with a simple prospective, evidence-based intervention associated with improved prescribing, use, and disposal. Source of Funding: none